Industry and Transactions · global
Samsung Biologics to Acquire PolyPeptide for CHF 1.46 Billion, Betting on the Peptide Drug Manufacturing Boom
Expanding from antibodies and antibody-drug conjugates into peptide active pharmaceutical ingredients, Samsung Biologics has proposed an all-cash offer of CHF 44.31 per share. Behind the deal is a global race for capacity driven by the rapid expansion of obesity and diabetes drugs.
The surge in demand for obesity and diabetes drugs is pushing pharmaceutical competition all the way to the production line. Samsung Biologics has launched an all-cash public tender offer valued at approximately CHF 1.46 billion to acquire Swiss contract development and manufacturing organization PolyPeptide, adding peptide active pharmaceutical ingredient development and mass-production capabilities to its existing antibody and antibody-drug conjugate businesses.
The offer price is CHF 44.31 per share, representing a premium of approximately 6.1% over PolyPeptide’s July 17 closing price of CHF 41.75. Depending on exchange rates and valuation methods, different sources have converted the transaction value to approximately US$1.8 billion or KRW 2.7 trillion. Samsung expects to launch the public tender offer by the end of August and aims to complete the transaction by year-end, subject to relevant regulatory and closing conditions.
The transaction already has the support of a key shareholder. Draupnir Holding, which owns approximately 55.65% of PolyPeptide’s shares, has committed to accept the offer, significantly increasing the certainty that Samsung will gain control. Under the publicly disclosed transaction plan, after completing the acquisition Samsung will also seek to squeeze out the remaining minority shareholders and delist PolyPeptide from the Swiss stock exchange.
PolyPeptide’s board said that, after reviewing various strategic options, it considers the cash offer attractive to shareholders. Joining Samsung would also provide access to greater funding, investment capacity, and operational scale. The Swiss company operates six peptide manufacturing facilities in Sweden, Belgium, France, India, and the United States. If the transaction is completed, Samsung will quickly gain cross-continental capacity and established process expertise without having to build a complete platform from scratch.
Peptide drugs fall between small molecules and large protein-based medicines, and their production involves highly specialized processes including amino acid sequence synthesis, purification, and quality control. The market for obesity and diabetes treatments, represented by GLP-1 drugs, has expanded in recent years, also prompting pharmaceutical companies to seek reliable active pharmaceutical ingredient capacity. Samsung’s move reflects how large biomanufacturers are seeking to use a broader range of technology platforms to meet customers’ needs from development through commercialization.
However, market growth does not mean the acquisition can immediately be converted into orders and profits. Available information has not yet disclosed integration costs, customer contract structures, capacity utilization rates, or additional investment requirements, while the public tender offer and minority shareholder squeeze-out procedures also remain to be completed. For Samsung, the real test will be whether it can effectively integrate PolyPeptide’s multinational peptide capacity into its global manufacturing network while retaining the company’s technology and customer base.